JP2010501479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010501479A5 JP2010501479A5 JP2009524014A JP2009524014A JP2010501479A5 JP 2010501479 A5 JP2010501479 A5 JP 2010501479A5 JP 2009524014 A JP2009524014 A JP 2009524014A JP 2009524014 A JP2009524014 A JP 2009524014A JP 2010501479 A5 JP2010501479 A5 JP 2010501479A5
- Authority
- JP
- Japan
- Prior art keywords
- arg
- amino acid
- shows
- amino acids
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83703006P | 2006-08-10 | 2006-08-10 | |
| US91747607P | 2007-05-11 | 2007-05-11 | |
| PCT/US2007/075728 WO2008019395A2 (en) | 2006-08-10 | 2007-08-10 | Compounds for improving learning and memory |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010501479A JP2010501479A (ja) | 2010-01-21 |
| JP2010501479A5 true JP2010501479A5 (enExample) | 2010-07-01 |
Family
ID=39033625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524014A Pending JP2010501479A (ja) | 2006-08-10 | 2007-08-10 | 学習および記憶を改善するための化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080108568A1 (enExample) |
| EP (1) | EP2061314A4 (enExample) |
| JP (1) | JP2010501479A (enExample) |
| AU (1) | AU2007281701A1 (enExample) |
| CA (1) | CA2659289A1 (enExample) |
| WO (1) | WO2008019395A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE513929T1 (de) * | 2006-01-27 | 2011-07-15 | Translational Genomics Res Inst | Gene mit einfluss auf die menschliche gedächtnisleistung |
| CN102088853A (zh) * | 2008-05-12 | 2011-06-08 | 安内斯蒂克斯公司 | 改善学习和记忆的化合物 |
| US9072730B2 (en) * | 2009-05-14 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease |
| EP2354789A1 (en) * | 2010-02-08 | 2011-08-10 | Sygnis Bioscience GmbH & Co. KG | Method for the identification of memory modulating compounds by assessing KIBRA expression |
| US20120010196A1 (en) * | 2010-04-02 | 2012-01-12 | Qin Quingyu | Methods of treating neurodegenerative disorders and diseases |
| WO2012006640A2 (en) * | 2010-07-09 | 2012-01-12 | Translational Genomics Research Institute | Compositions and methods useful in enhancement of memory |
| WO2013041238A1 (en) * | 2011-09-21 | 2013-03-28 | Sygnis Bioscience Gmbh & Co. Kg | Use of kibra peptides, hdac inhibitor or proteasome inhibitor for improving anxiety disorders |
| KR102276424B1 (ko) * | 2014-10-06 | 2021-07-12 | 삼성전자주식회사 | 로-키나제 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도 |
| EP3367898A4 (en) * | 2015-10-27 | 2019-07-03 | HRL Laboratories, LLC | TRANSCRANIAL CONTROL OF THE PROCEDURAL MEMORY BACKWARD FOR SENSITIVITY DETECTION |
| US11587644B2 (en) | 2017-07-28 | 2023-02-21 | The Translational Genomics Research Institute | Methods of profiling mass spectral data using neural networks |
| JP7766935B2 (ja) | 2020-01-09 | 2025-11-11 | ウールジー・ファーマシューティカルズ・インコーポレイテッド | 皮質性認知症に関連する徘徊を治療する方法 |
| JP2023518707A (ja) | 2020-03-25 | 2023-05-08 | ウールジー・ファーマシューティカルズ・インコーポレイテッド | タンパク質症に関連する徘徊を治療する方法 |
| WO2021216139A1 (en) * | 2020-04-23 | 2021-10-28 | Woolsey Pharmaceuticals, Inc | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| WO2021257122A1 (en) * | 2020-06-15 | 2021-12-23 | Woolsey Pharmaceuticals, Inc | Methods of using rho kinase inhibitors to treat vascular dementia |
| US20230263806A1 (en) * | 2020-07-14 | 2023-08-24 | Woolsey Pharmaceuticals, Inc. | Methods of treating proteinopathies |
| CN112010805B (zh) * | 2020-08-26 | 2023-12-05 | 山东威高药业股份有限公司 | 一种盐酸法舒地尔的精制方法 |
| CA3188722A1 (en) * | 2020-08-27 | 2022-03-03 | Thomas Macallister | Methods of treating age-related cognitive decline |
| CA3188718A1 (en) * | 2020-08-28 | 2022-03-03 | Thomas Macallister | Methods of treating age-related cognitive decline |
| US20240299408A1 (en) | 2020-10-22 | 2024-09-12 | Woolsey Pharmaceuticals, Inc. | Methods of treating 4-repeat tauopathies |
| MX2024006505A (es) | 2021-11-29 | 2024-06-05 | Woolsey Pharmaceuticals Inc | Metodos para tratar la agitacion y otros sintomas conductuales asociados con la demencia. |
| CN114457154B (zh) * | 2022-04-13 | 2022-06-28 | 山东第一医科大学附属省立医院(山东省立医院) | KIBRA rs17070145检测试剂在制备嗅觉功能评价试剂盒中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5993054A (ja) * | 1982-11-18 | 1984-05-29 | Asahi Chem Ind Co Ltd | イソキノリンスルホン酸アミド誘導体 |
| US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
| JPH0667926B2 (ja) * | 1985-11-12 | 1994-08-31 | 旭化成工業株式会社 | 環状のイソキノリンスルホンアミド誘導体 |
| US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| JP3464012B2 (ja) * | 1993-04-05 | 2003-11-05 | 旭化成株式会社 | 精神症候治療剤 |
| DE69606721T2 (de) * | 1995-07-03 | 2000-06-21 | Asahi Kasei Kogyo K.K., Osaka | 1-(5-isochinolinsulfonyl)homopiperazin hydrochlorid |
| KR100396171B1 (ko) * | 1998-08-10 | 2003-08-27 | 아사히 가세이 가부시키가이샤 | 염산 파수딜의 경구 서방성 제제 |
| US7655423B2 (en) * | 1999-06-14 | 2010-02-02 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
| US20020173535A1 (en) * | 2001-02-07 | 2002-11-21 | Renshaw Perry F. | Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
| CA2449794A1 (en) * | 2001-04-27 | 2002-11-07 | Cold Spring Harbor Laboratory | Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical pkm activity |
| DE10153605A1 (de) * | 2001-11-02 | 2003-05-28 | Morphochem Ag Komb Chemie | Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens |
| US20050014783A1 (en) * | 2003-05-29 | 2005-01-20 | Schering Aktiengesellschaft | Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
| WO2005117896A1 (de) * | 2004-06-03 | 2005-12-15 | Schering Aktiengesellschaft | Formulierungen, die fasudil, eine matrix und einem mantel enthalten |
| ATE513929T1 (de) * | 2006-01-27 | 2011-07-15 | Translational Genomics Res Inst | Gene mit einfluss auf die menschliche gedächtnisleistung |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
-
2007
- 2007-08-10 AU AU2007281701A patent/AU2007281701A1/en not_active Abandoned
- 2007-08-10 EP EP07840881A patent/EP2061314A4/en not_active Withdrawn
- 2007-08-10 CA CA002659289A patent/CA2659289A1/en not_active Abandoned
- 2007-08-10 WO PCT/US2007/075728 patent/WO2008019395A2/en not_active Ceased
- 2007-08-10 JP JP2009524014A patent/JP2010501479A/ja active Pending
- 2007-08-10 US US11/837,326 patent/US20080108568A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240382436A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| Oka et al. | Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension | |
| US8088951B2 (en) | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss | |
| US11278550B2 (en) | Compositions and methods for the treatment of Prader-Willi syndrome | |
| US9107868B2 (en) | Neuronal pain pathway | |
| US9402826B2 (en) | Neuronal pain pathway modulators | |
| CN109475539B (zh) | 帕金森氏病的治疗 | |
| US10676747B2 (en) | Methods for improving cognitive function via modulation of quinone reductase 2 | |
| CN107249583A (zh) | 乳酸脱氢酶抑制剂以及含有该抑制剂的抗癫痫剂 | |
| JP2011519973A (ja) | 学習及び記憶を改善するための化合物関連出願に関する情報 | |
| JP2012508249A5 (enExample) | ||
| US11060144B2 (en) | Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype | |
| JP2015535247A5 (enExample) | ||
| JP2005508872A5 (enExample) | ||
| JP2023088996A (ja) | 癌治療 | |
| JP2024543963A (ja) | 高い安定性及び遺伝子サイレンシング活性を有する低分子干渉rna分子のための修飾パターン | |
| JP2007527859A (ja) | グリコーゲンシンターゼキナーゼ−3阻害剤 | |
| JP2012521198A5 (enExample) | ||
| RU2011101771A (ru) | Педиатрические композиции для лечения рассеянного склероза | |
| US20060167026A1 (en) | Antipsychotic molecular-targeting epithelial growth factor receptor | |
| CN107296807A (zh) | Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用 | |
| Samarska et al. | S1P1 receptor modulation preserves vascular function in mesenteric and coronary arteries after CPB in the rat independent of depletion of lymphocytes | |
| KR20220035275A (ko) | 다발성 골수종 치료 | |
| WO2003084542A1 (en) | Neurotrophic factor production accelerator | |
| JP6987749B2 (ja) | Skチャネル阻害剤による学習障害および他の神経障害の治療 |